Aspire Biopharma Holdings (ASBP) Retained Earnings (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has reported Retained Earnings for 6 consecutive years, with $43.5 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Retained Earnings rose 310.18% year-over-year to $43.5 million in Q2 2026; TTM through Jun 2026 was $43.5 million, a 310.18% increase from a year earlier, with the FY2025 full-year figure at -$27.3 million, down 881.48% from the prior year.
• Retained Earnings was $43.5 million for Q2 2026 at Aspire Biopharma Holdings, up from $34.3 million in the prior quarter.
• Over five years, Retained Earnings peaked at $43.5 million in Q2 2026 and troughed at -$27.3 million in Q4 2025.
• A 5-year average of -$6.0 million and a median of -$10.3 million in 2023 frame the typical range for Retained Earnings.
• Across the five-year window, Retained Earnings tumbled 38913.23% in 2022 and surged 310.18% in 2026, its largest moves.
• Over 5 years, Retained Earnings stood at -$9.9 million in 2022, then retreated by 13.57% to -$11.3 million in 2023, then jumped by 75.4% to -$2.8 million in 2024, then plunged by 881.48% to -$27.3 million in 2025, then soared by 259.61% to $43.5 million in 2026.
• The last three Retained Earnings figures came in at $43.5 million (Q2 2026), $34.3 million (Q1 2026), and -$27.3 million (Q4 2025), per Business Quant data.